Sanofi's oral TNFα inhibitor approved for clinical trials in China.

On March 1st, the China National Medical Products Administration's Center for Drug Evaluation (CDE) website announced that Sanofi's Class 1 new drug SAR441566 has been approved for clinical trials. It is intended to be developed for the treatment of moderate to severe rheumatoid arthritis (RA) and moderate to severe plaque psoriasis. Public information indicates that SAR441566 is an oral TNFα inhibitor. According to Sanofi's public information, SAR441566 is part of the company's next generation of oral medications, serving as a TNFR1 signaling pathway inhibitor. These types of drugs can target core disease pathways and have the convenience of oral administration along with the efficacy of antibodies. In the phase 1b clinical trial for treating psoriasis, SAR441566 demonstrated good safety and tolerability while improving symptoms. According to information from the ClinicalTrials platform, SAR441566 is currently in phase 2 clinical trials for the treatment of psoriasis and rheumatoid arthritis.